Form 4 for REGN Regeneron Pharmaceuticals
Accepted 2023-02-07 00:00:00 ET · period of report 2023-02-03 · accession 0001883850-23-000035 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2023-02-07 | 2023-02-03+ | REGN | Landry Robert E | EVP Fin CFO | S - Sale+OE | $776.80 | -1,491 | 32.7K | -4% | -$1.16M |
| D | 2023-02-07 | 2023-02-03 | REGN | Landry Robert E | EVP Fin CFO | F - Tax | $774.29 | -2,248 | 32.9K | -6% | -$1.74M |
| D | 2023-02-07 | 2023-02-03 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $381.92 | +3,000 | 35.1K | +9% | +$1.15M |
| D | 2023-02-07 | 2023-02-03 | REGN | Landry Robert E | EVP Fin CFO | M - OptEx | $0.00 | -3,000 | 800 | -79% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-06 | S | D | 49 | $789.05 | 32,324 | D | — | — | |
| 2 | Common | Common Stock | 2023-02-06 | S | D | 10 | $790.41 | 32,314 | D | — | — | |
| 3 | Common | Common Stock | 2023-02-06 | S | D | 3 | $791.00 | 32,311 | D | — | — | |
| 4 | Common | Common Stock | 2023-02-06 | S | D | 2 | $793.33 | 32,309 | D | — | — | |
| 5 | Common | Common Stock | 2023-02-06 | S | D | 99 | $794.61 | 32,210 | D | — | — | (F6) Represents volume-weighted average price of sales of 99 shares of Company stock on February 6, 2023 at prices ranging from $794.28 to $794.85. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. |
| 6 | Common | Common Stock | 2023-02-06 | S | D | 59 | $795.41 | 32,151 | D | — | — | (F7) Represents volume-weighted average price of sales of 59 shares of Company stock on February 6, 2023 at prices ranging from $795.26 to $795.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. |
| 7 | Common | Common Stock | 2023-02-06 | S | D | 18 | $796.43 | 32,133 | D | — | — | (F8) Represents volume-weighted average price of sales of 18 shares of Company stock on February 6, 2023 at prices ranging from $796.35 to $796.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. |
| 8 | Common | Common Stock | 2023-02-06 | S | D | 99 | $788.62 | 32,373 | D | — | — | (F5) Represents volume-weighted average price of sales of 99 shares of Company stock on February 6, 2023 at prices ranging from $788.48 to $788.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. |
| 9 | Common | Common Stock | 2023-02-06 | S | D | 58 | $787.47 | 32,472 | D | — | — | |
| 10 | Common | Common Stock | 2023-02-06 | S | D | 85 | $786.45 | 32,530 | D | — | — | (F4) Represents volume-weighted average price of sales of 85 shares of Company stock on February 6, 2023 at prices ranging from $786.03 to $786.66. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. |
| 11 | Common | Common Stock | 2023-02-06 | S | D | 78 | $785.88 | 32,615 | D | — | — | (F3) Represents volume-weighted average price of sales of 78 shares of Company stock on February 6, 2023 at prices ranging from $785.85 to $785.90. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. |
| 12 | Common | Common Stock | 2023-02-06 | S | D | 28 | $797.43 | 32,105 | D | — | — | |
| 13 | Common | Common Stock | 2023-02-06 | S | D | 51 | $783.05 | 32,806 | D | — | — | |
| 14 | Common | Common Stock | 2023-02-03 | F | D | 2,248 | $774.29 | 32,857 | D | — | — | |
| 15 | Common | Common Stock | 2023-02-03 | M | A | 3,000 | $381.92 | 35,105 | D | — | — | |
| 16 | Common | Common Stock | 2023-02-03 | S | D | 739 | $764.50 | 32,105 | D | — | — | |
| 17 | Common | Common Stock | 2023-02-06 | S | D | 113 | $784.27 | 32,693 | D | — | — | (F2) Represents volume-weighted average price of sales of 113 shares of Company stock on February 6, 2023 at prices ranging from $784.02 to $784.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 6, 2023 at each separate price. |
| 18 | Derivative | Non-Qualified Stock Option (right to buy) | 2023-02-03 | M | D | 3,000 | $0.00 | 800 | D | $381.92 · — to 2026-12-16 | 3,000 Common Stock | (F9) The stock option award vests in four equal annual installments, commencing one year after the date of grant. |